Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: As ergotamine tartrate: Inhale single dose (360 mcg) at the onset of attack and repeat at 5-min intervals, if necessary. Max: 6 inhalations/24 hr, 15 inhalations/wk.

Adult: As ergotamine tartrate: 2 mg on the onset of attack, then 2 mg every 30 min if necessary. Max: 6 mg/24 hr, 10 mg/wk.
Renal Impairment
Hepatic Impairment
Cách dùng
May be taken with or without food.
Chống chỉ định
Patient w/ severe or uncontrolled HTN, severe or persistent sepsis, shock, peripheral vascular disease, temporal arteritis, ischaemic heart disease, hyperthyroidism; basilar or hemiplegic migraine. Renal or hepatic impairment. Pregnancy. Concomitant admin w/ potent CYP3A4 inhibitors (e.g. azole antifungals, protease inhibitors, macrolide antibiotics).
Thận trọng
Patient w/ anaemia. Lactation.
Phản ứng phụ
Nausea and vomiting, abdominal pain, tingling of fingers and toes, weakness, muscle pains in the extremities and numbness, localised oedema, itching, bradycardia, transient tachycardia.
PO/Rectal/SL: X
Thông tin tư vấn bệnh nhân
May cause dizziness and feelings of anxiety, if affected, do not drive or operate machinery.
Evaluate CV status prior to initiation and periodically thereafter.
Quá liều
Symptoms: Numbness, vomiting, tingling, pain, cyanosis of the extremities associated w/ diminished or absent peripheral pulses; HTN or hypotension; stupor, drowsiness, convulsions, shock, coma; reversible bilateral papillitis w/ ring scotomata. Management: Maintain adequate pulmonary ventilation, correction of hypotension and control or BP and convulsions. Keep the extremities warm to treat peripheral vasospasm. Vasodilators may be beneficial.
Tương tác
Increased risk of peripheral vasoconstriction w/ β-blockers. Increased vasoconstrictor effect w/ sympathomimetics (e.g. epinephrine).
Potentially Fatal: Increased risk of ergotism w/ potent CYP3A4 inhibitors (e.g. azole antifungals, protease inhibitors, macrolide antibiotics).
Food Interaction
May enhance toxicity w/ grapefruit juice.
Tác dụng
Description: Ergotamine has marked vasoconstrictor effects and partial agonistic action at serotonin (5-HT) receptors. It causes constriction of peripheral and cranial blood vessels and produces central vasomotor center depression. It also has a powerful oxytocic action on the uterus.
Absorption: Poorly absorbed from the GI tract. Bioavailability: Approx ≤5%. Time to peak plasma concentration: 2 hr (oral).
Distribution: Crosses the blood-brain barrier; enters breast milk. Volume of distribution: 1.85 L/kg. Plasma protein binding: Approx 93-98%.
Metabolism: Undergoes extensive hepatic metabolism, including high first-pass effect.
Excretion: Via faeces (90%, mainly as metabolites); urine (approx 4%). Biphasic elimination half-life: Approx 2 hr (initial phase); 21 hr (terminal phase).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Ergotamine, CID=8223, (accessed on Jan. 22, 2020)

Bảo quản
Store between 20-25°C. Protect form heat and light.
Phân loại MIMS
Phân loại ATC
N02CA02 - ergotamine ; Belongs to the class of ergot alkaloids preparations. Used to relieve migraine.
Anon. Ergotamine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 20/01/2016.

Buckingham R (ed). Ergotamine Tartrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 20/01/2016.

Ergomar Tablet, Orally Disintegrating (Rosedale Therapeutics). DailyMed. Source: U.S. National Library of Medicine. Accessed 20/01/2016.

Joint Formulary Committee. Ergotamine Tartrate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 20/01/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Ergotamine Tartrate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 20/01/2016.

Medihaler Ergotamine Aerosol, Metered (3M Riker). DailyMed. Source: U.S. National Library of Medicine. Accessed 20/01/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Ergotamine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in